David Tulasne Signalling, Apoptosis and Cancer
Course and current status
Scientific Career and Professional Experiences
Group leader of the team "Signalling, Apoptosis and Cancer" in the UMR8161, CNRS, Institute of Biology of Lille (IBL)
2017 Director of research, INSERM, IBL
2006 Research Associate 1ère classe INSERM, IBL
2002 Research Associate 2ème classe INSERM, IBL
1999 -2001 Postdoctoral researcher, Laboratory of Dr SP. Watson, Department of Pharmacology, University of Oxford, UK.
1995-1999 PhD student. Laboratory of Dr B. Vandenbunder. Régulation des processus invasifs, de l’Angiogenèse et de l’Apoptose. CNRS EP560, IBL.
Academic Education
2005 “Habilitation à diriger des recherches”, University of Lille
1999 PhD, Life Sciences and Heath, University of Lille
1995 Master II, Life Sciences and Heath
1993 Master I Cellular Biology
1992 Licence Biology
Scientific summary
The Hepatocyte growth factor/Scatter Factor (HGF/SF), the specific ligand of the receptor tyrosine kinase Met, induces multiple biological responses including proliferation, invasion, morphogenesis and survival of epithelial cells, which are essential for epithelial homeostasis. Indeed, the HGF/SF-Met system is essential for embryonic development and tissue regeneration in adults. However, deregulated HGF/SF-Met signaling is involved in tumor progression in particular by promoting invasion and metastasis in numerous types of cancer. Our goal is to characterize the molecular mechanism induced by the receptor tyrosine kinase Met to regulate the epithelial homeostasis.
